Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Interleukin (IL)-10 is a pleiotropic cytokine with potent inhibitory effects towards T(H)-1 cells. IL-10 inhibits secretion of IL-2 and interferon (IFN)gamma by T cells and downregulates major histocompatibility complex antigens. A variety of tumor cells secrete IL-10, which can inhibit growth of tumor-specific cytotoxic T cells. IL-10 expression has also been detected in B-cell lymphomas and Hodgkin's disease (HD), and it has been suggested that the cytokine is involved in the pathogenesis of these tumors. We analyzed levels of IL-10 in pretreatment sera of 64 patients with HD and healthy controls using a sensitive enzyme-linked immunosorbent assay. Patients with biopsy-proven HD were enrolled in trials of the German Hodgkin Study Group (GHSG). Elevated IL-10 levels were detected in the sera of nine patients with HD (14.1%) (range 4.5-225.6 pg/ml with a mean of 61.5 pg/ml). IL-10 was not detectable in a control population of healthy volunteers (n =90). Multivariate analyses revealed a significant correlation between elevated IL-10 levels and higher age (over 45 years) but not with any other factors defined by the international prognostic factor score. Patients with elevated IL-10 levels had a significantly lower freedom from treatment failure rate as detected in univariate and multivariate tests. Thus, IL-10 may serve as an independent prognostic factor for HD patients.
Bohlen
H
H
Klinik I für Innere Medizin der Universität zu Köln, Germany. Heribert.Bohlen@Medizin.uni-koeln.de
Kessler
M
M
Sextro
M
M
Diehl
V
V
Tesch
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000139:chemically induced; D006801:Humans; D016753:Interleukin-10 / Q000097:blood* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D016753:Interleukin-10